Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc Stock Analysis & Ratings

AMLX Stock Chart & Stats

Day’s Range$7.3 - $8.75
52-Week Range$6.51 - $33.41
Previous Close$7.48
Average Volume (3M)663.64K
Market Cap$488.95M
P/E RatioN/A
Next EarningsMay 12, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)0.00



P/E Ratio Range

Currently, no data available
Please return soon. This page is being updated.
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $6.51 and its highest was $33.41 in the past 12 months.
    What is Amylyx Pharmaceuticals Inc’s market cap?
    Amylyx Pharmaceuticals Inc’s market cap is $488.95M.
      What is Amylyx Pharmaceuticals Inc’s price target?
      The average price target for Amylyx Pharmaceuticals Inc is $25.33. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $35.00 ,the lowest forecast is $10.00. The average price target represents 199.76% Increase from the current price of $8.45.
        What do analysts say about Amylyx Pharmaceuticals Inc?
        Amylyx Pharmaceuticals Inc’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
          Amylyx Pharmaceuticals Inc’s upcoming earnings report date is May 12, 2022 which is 4 days ago.
            How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
            Amylyx Pharmaceuticals Inc released its earnings results on Mar 30, 2022. The company reported -$4.23 earnings per share for the quarter, beating the consensus estimate of -$6.935 by $2.705.
              Is Amylyx Pharmaceuticals Inc overvalued?
              According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
                Does Amylyx Pharmaceuticals Inc pay dividends?
                Amylyx Pharmaceuticals Inc does not currently pay dividends.
                What is Amylyx Pharmaceuticals Inc’s EPS estimate?
                Amylyx Pharmaceuticals Inc’s EPS estimate is -$0.93.
                  How many shares outstanding does Amylyx Pharmaceuticals Inc have?
                  Amylyx Pharmaceuticals Inc has 57,860,000 shares outstanding.
                    What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
                    Amylyx Pharmaceuticals Inc reported an EPS of -$4.23 in its last earnings report, beating expectations of -$6.935. Following the earnings report the stock price went up 12.968%.
                      Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
                      Among the largest hedge funds holding Amylyx Pharmaceuticals Inc’s share is Falcon Edge Capital, LP. It holds Amylyx Pharmaceuticals Inc’s shares valued at 8M.


                        Amylyx Pharmaceuticals Inc Stock Analysis

                        The Amylyx Pharmaceuticals Inc stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Amylyx Pharmaceuticals Inc

                        Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

                        Similar Stocks
                        No data currently available

                        Popular Stocks

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis